Evaluation of siddha trial drug Sengatharipattai kudineer(internal) and Murungai pushpam ennai (external) for Balakarappan (Atopic dermatitis)

PHASE II NON RANDOMIZED CLINICAL STUDY ON BALA KARAPPAN (ATOPIC DERMATITIS) WITH EVALUATION OF SIDDHA TRIAL DRUG "SENGATHARIPATTAI KUDINEER" (INTERAL) AND MURUNGAI PUSHPAM ENNAI (EXTERNAL) - Balakarappan

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/11/029181

Enrollment

Registered

2020-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Sengatharai Pattai Kudineer: 6-30 ml of decoction bd for 21 days Intervention2: Murungai Pushpam Ennai: External application 5ml bd for 21 days Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: Itching & Scratching Erythema Papules with edema Vesicles Oozing Crusthing Scaling Lichenification

Exclusion criteria

Exclusion criteria: Scabies Photo dermatitis Ichthyosis Pitriyasis alba Cheillitis Psoriasis

Design outcomes

Primary

Measure	Time frame
Reduction in EASI Score Reduction in clinical Symptoms Photos evidence before and after treatmentTimepoint: 21 days	—

Secondary

Measure	Time frame
Comparing Safety parameters before and after treatmentTimepoint: 21 days	—

Countries

India

Contacts

Public ContactDr Sowmiya D

Government Siddha Medical College Chennai

ranimoorthybsms19@gmail.com9442286863

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026